CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX),
Monday announced that its New Drug Submission or NDS for exagamglogene
autotemcel has been accepted for Priority Review by Health Canada for the
treatment of patients aged 12 years and older with sickle cell disease or SCD
and transfusion-dependent beta thalassemia or TDT.

SCD and TDT are debilitating, progressive, life shortening genetic disease,
which lead to reduced life expectancy, decreased quality of life and reduced
lifetime earnings and productivity.

Vertex explained that exagamglogene autotemcel is a gene-edited cell therapy
where a patient's own hematopoietic stem and progenitor cells are edited to
increase the production of fetal hemoglobin in red blood cells.

NDS is supported by data from the ongoing Phase 3 studies, CLIMB-111 and
CLIMB-121, as well as an ongoing long-term follow-up study, CLIMB-131.

Currently, Vertex's stock is falling 0.19 percent, to $416.83 on the Nasdaq.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX